Medical - Devices
Compare Stocks
5 / 10Stock Comparison
AHCO vs HCSG vs OPCH vs EHAB vs PTCT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
Biotechnology
AHCO vs HCSG vs OPCH vs EHAB vs PTCT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Biotechnology |
| Market Cap | $1.59B | $1.60B | $3.25B | $706M | $5.35B |
| Revenue (TTM) | $2.86B | $1.84B | $5.67B | $1.06B | $827M |
| Net Income (TTM) | $-80M | $59M | $206M | $-3M | $-187M |
| Gross Margin | 1.8% | 13.3% | 18.0% | 34.5% | 49.7% |
| Operating Margin | 7.2% | 3.0% | 5.9% | 7.2% | -8.3% |
| Forward P/E | 11.7x | 20.8x | 11.1x | 22.8x | 8.3x |
| Total Debt | $1.90B | $25M | $0.00 | $500M | $492M |
| Cash & Equiv. | $106M | $161M | $233M | $44M | $985M |
AHCO vs HCSG vs OPCH vs EHAB vs PTCT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 22 | May 26 | Return |
|---|---|---|---|
| AdaptHealth Corp. (AHCO) | 100 | 65.0 | -35.0% |
| Healthcare Services… (HCSG) | 100 | 128.1 | +28.1% |
| Option Care Health,… (OPCH) | 100 | 74.7 | -25.3% |
| Enhabit, Inc. (EHAB) | 100 | 60.0 | -40.0% |
| PTC Therapeutics, I… (PTCT) | 100 | 161.0 | +61.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AHCO vs HCSG vs OPCH vs EHAB vs PTCT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, AHCO doesn't own a clear edge in any measured category.
HCSG ranks third and is worth considering specifically for income & stability.
- Dividend streak 20 yrs, beta 1.12
- 7.3% ROA vs PTCT's -6.8%
OPCH is the clearest fit if your priority is quality.
- 3.6% margin vs PTCT's -22.6%
EHAB has the current edge in this matchup, primarily because of its strength in sleep-well-at-night and defensive.
- Lower volatility, beta 0.44, Low D/E 88.6%, current ratio 1.63x
- Beta 0.44, current ratio 1.63x
- Beta 0.44 vs PTCT's 1.13
- +68.0% vs OPCH's -37.9%
PTCT is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 114.5%, EPS growth 264.5%, 3Y rev CAGR 35.3%
- 7.3% 10Y total return vs OPCH's 97.2%
- 114.5% revenue growth vs AHCO's -0.5%
- Lower P/E (8.3x vs 22.8x)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 114.5% revenue growth vs AHCO's -0.5% | |
| Value | Lower P/E (8.3x vs 22.8x) | |
| Quality / Margins | 3.6% margin vs PTCT's -22.6% | |
| Stability / Safety | Beta 0.44 vs PTCT's 1.13 | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +68.0% vs OPCH's -37.9% | |
| Efficiency (ROA) | 7.3% ROA vs PTCT's -6.8% |
AHCO vs HCSG vs OPCH vs EHAB vs PTCT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
AHCO vs HCSG vs OPCH vs EHAB vs PTCT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
AHCO leads in 2 of 6 categories
HCSG leads 2 • EHAB leads 1 • OPCH leads 0 • PTCT leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
AHCO leads this category, winning 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
OPCH is the larger business by revenue, generating $5.7B annually — 6.9x PTCT's $827M. OPCH is the more profitable business, keeping 3.6% of every revenue dollar as net income compared to PTCT's -22.6%. On growth, AHCO holds the edge at +41.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2.9B | $1.8B | $5.7B | $1.1B | $827M |
| EBITDAEarnings before interest/tax | $504M | $72M | $406M | $98M | -$37M |
| Net IncomeAfter-tax profit | -$80M | $59M | $206M | -$3M | -$187M |
| Free Cash FlowCash after capex | $219M | $139M | $244M | $81M | -$229M |
| Gross MarginGross profit ÷ Revenue | +1.8% | +13.3% | +18.0% | +34.5% | +49.7% |
| Operating MarginEBIT ÷ Revenue | +7.2% | +3.0% | +5.9% | +7.2% | -8.3% |
| Net MarginNet income ÷ Revenue | -2.8% | +3.2% | +3.6% | -0.3% | -22.6% |
| FCF MarginFCF ÷ Revenue | +7.7% | +7.6% | +4.3% | +7.6% | -27.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +41.2% | +6.6% | +1.3% | +1.9% | -76.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -140.0% | +175.0% | +3.6% | +2.9% | -100.3% |
Valuation Metrics
AHCO leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 8.3x trailing earnings, PTCT trades at a 70% valuation discount to HCSG's 27.5x P/E. On an enterprise value basis, PTCT's 5.4x EV/EBITDA is more attractive than HCSG's 22.4x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.6B | $1.6B | $3.2B | $706M | $5.3B |
| Enterprise ValueMkt cap + debt − cash | $3.4B | $1.5B | $3.0B | $1.2B | $4.9B |
| Trailing P/EPrice ÷ TTM EPS | -22.56x | 27.54x | 16.34x | -152.10x | 8.29x |
| Forward P/EPrice ÷ next-FY EPS est. | 11.75x | 20.83x | 11.12x | 22.84x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 5.66x | 22.38x | 7.38x | 13.47x | 5.42x |
| Price / SalesMarket cap ÷ Revenue | 0.49x | 0.87x | 0.57x | 0.67x | 3.09x |
| Price / BookPrice ÷ Book value/share | 1.04x | 3.19x | 2.56x | 1.24x | — |
| Price / FCFMarket cap ÷ FCF | 7.27x | 11.49x | 12.56x | 10.73x | 7.61x |
Profitability & Efficiency
HCSG leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
OPCH delivers a 15.3% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-5 for AHCO. HCSG carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to AHCO's 1.25x. On the Piotroski fundamental quality scale (0–9), HCSG scores 7/9 vs OPCH's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -5.1% | +11.8% | +15.3% | -0.6% | — |
| ROA (TTM)Return on assets | -1.8% | +7.3% | +6.0% | -0.3% | -6.8% |
| ROICReturn on invested capital | +4.0% | +9.0% | +15.3% | +4.5% | — |
| ROCEReturn on capital employed | +5.0% | +7.7% | +12.8% | +6.0% | +55.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 | 5 | 6 | 7 |
| Debt / EquityFinancial leverage | 1.25x | 0.05x | — | 0.89x | — |
| Net DebtTotal debt minus cash | $1.8B | -$136M | -$233M | $456M | -$492M |
| Cash & Equiv.Liquid assets | $106M | $161M | $233M | $44M | $985M |
| Total DebtShort + long-term debt | $1.9B | $25M | $0 | $500M | $492M |
| Interest CoverageEBIT ÷ Interest expense | 0.65x | 33.02x | 5.50x | 0.83x | -1.67x |
Total Returns (Dividends Reinvested)
Evenly matched — HCSG and EHAB and PTCT each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PTCT five years ago would be worth $16,026 today (with dividends reinvested), compared to $4,453 for AHCO. Over the past 12 months, EHAB leads with a +68.0% total return vs OPCH's -37.9%. The 3-year compound annual growth rate (CAGR) favors HCSG at 14.1% vs OPCH's -9.7% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +21.3% | +28.6% | -35.6% | +51.6% | -16.0% |
| 1-Year ReturnPast 12 months | +42.4% | +55.8% | -37.9% | +68.0% | +58.2% |
| 3-Year ReturnCumulative with dividends | -2.8% | +48.6% | -26.3% | +2.1% | +16.1% |
| 5-Year ReturnCumulative with dividends | -55.5% | -21.1% | +18.0% | -44.9% | +60.3% |
| 10-Year ReturnCumulative with dividends | +20.9% | -26.8% | +97.2% | -44.9% | +733.2% |
| CAGR (3Y)Annualised 3-year return | -0.9% | +14.1% | -9.7% | +0.7% | +5.1% |
Risk & Volatility
EHAB leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
EHAB is the less volatile stock with a 0.44 beta — it tends to amplify market swings less than PTCT's 1.13 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EHAB currently trades 96.9% from its 52-week high vs OPCH's 56.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.83x | 1.12x | 0.48x | 0.44x | 1.13x |
| 52-Week HighHighest price in past year | $13.43 | $24.39 | $36.80 | $14.22 | $87.50 |
| 52-Week LowLowest price in past year | $7.95 | $12.66 | $18.01 | $6.47 | $37.94 |
| % of 52W HighCurrent price vs 52-week peak | +87.3% | +91.5% | +56.4% | +96.9% | +73.7% |
| RSI (14)Momentum oscillator 0–100 | 38.2 | 61.8 | 22.5 | 58.6 | 45.3 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 676K | 2.4M | 1.3M | 1.0M |
Analyst Outlook
HCSG leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: AHCO as "Buy", HCSG as "Hold", OPCH as "Buy", EHAB as "Hold", PTCT as "Buy". Consensus price targets imply 59.0% upside for OPCH (target: $33) vs -1.8% for EHAB (target: $14).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $12.00 | $24.50 | $33.00 | $13.53 | $89.67 |
| # AnalystsCovering analysts | 12 | 15 | 14 | 11 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | 20 | 1 | 0 | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.9% | +9.5% | 0.0% | 0.0% |
AHCO leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). HCSG leads in 2 (Profitability & Efficiency, Analyst Outlook). 1 tied.
AHCO vs HCSG vs OPCH vs EHAB vs PTCT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is AHCO or HCSG or OPCH or EHAB or PTCT a better buy right now?
For growth investors, PTC Therapeutics, Inc.
(PTCT) is the stronger pick with 114. 5% revenue growth year-over-year, versus -0. 5% for AdaptHealth Corp. (AHCO). PTC Therapeutics, Inc. (PTCT) offers the better valuation at 8. 3x trailing P/E, making it the more compelling value choice. Analysts rate AdaptHealth Corp. (AHCO) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AHCO or HCSG or OPCH or EHAB or PTCT?
On trailing P/E, PTC Therapeutics, Inc.
(PTCT) is the cheapest at 8. 3x versus Healthcare Services Group, Inc. at 27. 5x. On forward P/E, Option Care Health, Inc. is actually cheaper at 11. 1x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — AHCO or HCSG or OPCH or EHAB or PTCT?
Over the past 5 years, PTC Therapeutics, Inc.
(PTCT) delivered a total return of +60. 3%, compared to -55. 5% for AdaptHealth Corp. (AHCO). Over 10 years, the gap is even starker: PTCT returned +733. 2% versus EHAB's -44. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AHCO or HCSG or OPCH or EHAB or PTCT?
By beta (market sensitivity over 5 years), Enhabit, Inc.
(EHAB) is the lower-risk stock at 0. 44β versus PTC Therapeutics, Inc. 's 1. 13β — meaning PTCT is approximately 155% more volatile than EHAB relative to the S&P 500. On balance sheet safety, Healthcare Services Group, Inc. (HCSG) carries a lower debt/equity ratio of 5% versus 125% for AdaptHealth Corp. — giving it more financial flexibility in a downturn.
05Which is growing faster — AHCO or HCSG or OPCH or EHAB or PTCT?
By revenue growth (latest reported year), PTC Therapeutics, Inc.
(PTCT) is pulling ahead at 114. 5% versus -0. 5% for AdaptHealth Corp. (AHCO). On earnings-per-share growth, the picture is similar: PTC Therapeutics, Inc. grew EPS 264. 5% year-over-year, compared to -185. 2% for AdaptHealth Corp.. Over a 3-year CAGR, PTCT leads at 35. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AHCO or HCSG or OPCH or EHAB or PTCT?
PTC Therapeutics, Inc.
(PTCT) is the more profitable company, earning 39. 4% net margin versus -2. 2% for AdaptHealth Corp. — meaning it keeps 39. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTCT leads at 49. 5% versus 2. 6% for HCSG. At the gross margin level — before operating expenses — PTCT leads at 95. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AHCO or HCSG or OPCH or EHAB or PTCT more undervalued right now?
On forward earnings alone, Option Care Health, Inc.
(OPCH) trades at 11. 1x forward P/E versus 22. 8x for Enhabit, Inc. — 11. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPCH: 59. 0% to $33. 00.
08Which pays a better dividend — AHCO or HCSG or OPCH or EHAB or PTCT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is AHCO or HCSG or OPCH or EHAB or PTCT better for a retirement portfolio?
For long-horizon retirement investors, Option Care Health, Inc.
(OPCH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 48)). Both have compounded well over 10 years (OPCH: +97. 2%, HCSG: -26. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AHCO and HCSG and OPCH and EHAB and PTCT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AHCO is a small-cap quality compounder stock; HCSG is a small-cap quality compounder stock; OPCH is a small-cap deep-value stock; EHAB is a small-cap quality compounder stock; PTCT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.